ENTA hasn't disclosed whether there is a backup RNA-destabilizer in the pipeline, but I think it's pretty likely there is. The question, of course, is whether the safety problem seen with EDP-721 is compound-specific or class-specific.
The hit to the share price ought to be pretty modest inasmuch as EDP-721 was only in phase-1.
News 
Market Data 
Discover 
